Trial Profile

An observational, multicenter, longitudinal and cohort study assessing safety and efficacy of Ixazomib-based therapy in patients with relapsed/refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2021 Results of pooled analysis from INSIGHT MM, UVEA-IXA and REMIX; assessing the effectiveness of IRd in the overall RRMM, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
17 Jun 2021 Status changed from recruiting to completed as per results presented at the 26th Congress of the European Haematology Association
17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com